Lv1
60 积分 2022-03-31 加入
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape
1年前
已完结
Comparing development strategies for PD1/PDL1-based immunotherapies
1年前
已完结
Complications of Percutaneous Transhepatic Cholangiography and Biliary Drainage (PTCD)
1年前
已关闭
Early safety from a phase I, multicenter, open-label, dose de-escalation study of talimogene laherparepvec (T-VEC) in Japanese patients (pts) with unresectable stage IIIB-IV melanoma (MEL)
2年前
已关闭
Early safety from a phase I, multicenter, open-label, dose de-escalation study of talimogene laherparepvec (T-VEC) in Japanese patients (pts) with unresectable stage IIIB-IV melanoma (MEL)
2年前
已完结
